Predictive Biomarkers Market Size, Share & Trends Analysis Report By Indication, By Technology (Diagnostics, Drug Discovery & Development, Personalized Medicine, Disease Risk Assessment), By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 3 Business Days
Predictive Biomarkers Market Summary
The global predictive biomarkers market size was estimated at USD 24.30 billion in 2024 and is projected to reach USD 63.54 billion by 2030, growing at a CAGR of 18.02% from 2025 to 2030. The market is experiencing significant growth driven by several factors such as advancements in genomics and precision medicines, increased investment in research and development and rising demand for early detection and personalized treatments.
Research and development (R&D) is a major driver of growth in the predictive biomarkers market, fueling innovation and the discovery of new biomarker candidates. Genomics and precision medicine are at the forefront of medical technology, offering the potential for more targeted and effective treatments. Predictive biomarkers for the effects of interventions can reflect an individual's biological constituents ("host characteristics") or traits associated with the disease process or other medical conditions. The NHS and the government are making significant investments in these technologies, including the launch of the NHS Genomic Medicine Service. This service is dedicated to advancements in genomics to benefit patients by implementing genome sequencing, providing molecular diagnostics and genetic testing for cancer patients, and enhancing data integration to facilitate more effective treatments. Moreover, expertise in technology and data analytics with proficiency in developing new sequencing technologies, is
achieved through collaborations that drive innovation and advance precision medicine for instance, in April 2025, Illumnia collaborated with Tempus AI to accelerate adoption of next generation sequencing tests for patients.
The growing investment in research and development (R&D) is a key driver of the predictive biomarkers market. Pharmaceutical companies, biotech firms, and academic institutions are dedicating significant resources to discovering new biomarkers and advancing diagnostic technologies. One prominent application for biomarker identification is next-generation sequencing (NGS), which can rapidly detect millions of DNA copies within a gene. This technology enables comprehensive profiling of multiple genes and mutations in a short amount of time. For example, Illumina’s NovaSeq X platform offers high-throughput sequencing for analyzing large sequences of data and diagnose the condition of disease. The increasing funding and collaborative efforts in biomarker discovery lead to the development of more effective and accurate predictive tests. This, in turn, is accelerating the growth of the predictive biomarkers market, supporting the next generation of healthcare innovations.
There is an increasing demand for early disease detection and personalized treatments, which is one of the key driver in predictive biomarkers market. Biomarkers provide valuable insights into an individual's health, helping identify diseases in their early stages before symptoms appear. Early detection enables more effective interventions, improving patient outcomes and reducing treatment costs. An important application of predictive biomarkers is in oncology, which demonstrates resistance to treatment that continues to be a leading cause of mortality in breast cancer patients, driving the need for the development of predictive biomarkers.
Innovative approaches, such as omics technologies and artificial intelligence, are being explored to identify highly accurate molecular or imaging biomarkers, with the potential to enhance treatment outcomes. Biomarkers are even gaining popularity incorporation into clinical trials for safety and efficacy tests. Predictive biomarkers may also become a part of these trials tailoring of medicines according to patient needs. As healthcare systems shift toward individualized medicine, predictive biomarkers play a crucial role in optimizing treatment regimens and ensuring the right therapy for each patient.
Global Predictive Biomarkers Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global predictive biomarkers market report on the basis of indication, technology and region.
Thermo Fisher Scientific Inc.
Qiagen
F. Hoffmann-La Roche Ltd
Bio-Rad Laboratories, Inc
Illumina Inc.
Merck KGaA
Bio-Techne
Siemens Healthineers AG
PerkinElmer
Myriad Genetics, Inc.
Becton Dickinson
Danaher Corporation
Genomic Health, Inc.
PacBio
Predictive Biomarkers Market Summary
The global predictive biomarkers market size was estimated at USD 24.30 billion in 2024 and is projected to reach USD 63.54 billion by 2030, growing at a CAGR of 18.02% from 2025 to 2030. The market is experiencing significant growth driven by several factors such as advancements in genomics and precision medicines, increased investment in research and development and rising demand for early detection and personalized treatments.
Research and development (R&D) is a major driver of growth in the predictive biomarkers market, fueling innovation and the discovery of new biomarker candidates. Genomics and precision medicine are at the forefront of medical technology, offering the potential for more targeted and effective treatments. Predictive biomarkers for the effects of interventions can reflect an individual's biological constituents ("host characteristics") or traits associated with the disease process or other medical conditions. The NHS and the government are making significant investments in these technologies, including the launch of the NHS Genomic Medicine Service. This service is dedicated to advancements in genomics to benefit patients by implementing genome sequencing, providing molecular diagnostics and genetic testing for cancer patients, and enhancing data integration to facilitate more effective treatments. Moreover, expertise in technology and data analytics with proficiency in developing new sequencing technologies, is
achieved through collaborations that drive innovation and advance precision medicine for instance, in April 2025, Illumnia collaborated with Tempus AI to accelerate adoption of next generation sequencing tests for patients.
The growing investment in research and development (R&D) is a key driver of the predictive biomarkers market. Pharmaceutical companies, biotech firms, and academic institutions are dedicating significant resources to discovering new biomarkers and advancing diagnostic technologies. One prominent application for biomarker identification is next-generation sequencing (NGS), which can rapidly detect millions of DNA copies within a gene. This technology enables comprehensive profiling of multiple genes and mutations in a short amount of time. For example, Illumina’s NovaSeq X platform offers high-throughput sequencing for analyzing large sequences of data and diagnose the condition of disease. The increasing funding and collaborative efforts in biomarker discovery lead to the development of more effective and accurate predictive tests. This, in turn, is accelerating the growth of the predictive biomarkers market, supporting the next generation of healthcare innovations.
There is an increasing demand for early disease detection and personalized treatments, which is one of the key driver in predictive biomarkers market. Biomarkers provide valuable insights into an individual's health, helping identify diseases in their early stages before symptoms appear. Early detection enables more effective interventions, improving patient outcomes and reducing treatment costs. An important application of predictive biomarkers is in oncology, which demonstrates resistance to treatment that continues to be a leading cause of mortality in breast cancer patients, driving the need for the development of predictive biomarkers.
Innovative approaches, such as omics technologies and artificial intelligence, are being explored to identify highly accurate molecular or imaging biomarkers, with the potential to enhance treatment outcomes. Biomarkers are even gaining popularity incorporation into clinical trials for safety and efficacy tests. Predictive biomarkers may also become a part of these trials tailoring of medicines according to patient needs. As healthcare systems shift toward individualized medicine, predictive biomarkers play a crucial role in optimizing treatment regimens and ensuring the right therapy for each patient.
Global Predictive Biomarkers Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global predictive biomarkers market report on the basis of indication, technology and region.
- Indication Outlook (Revenue, USD Million, 2018 - 2030)
- Cancer
- Cardiovascular Diseases
- Neurological Diseases
- Immunological Diseases
- Others
- Technology Outlook (Revenue, USD Million, 2018 - 2030)
- Diagnostics
- Drug Discovery & Development
- Personalized Medicine
- Disease Risk Assessment
- Others
- Regional Outlook (Revenue in USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa
- Saudi Arabia
- South Africa
- UAE
- Kuwait
Thermo Fisher Scientific Inc.
Qiagen
F. Hoffmann-La Roche Ltd
Bio-Rad Laboratories, Inc
Illumina Inc.
Merck KGaA
Bio-Techne
Siemens Healthineers AG
PerkinElmer
Myriad Genetics, Inc.
Becton Dickinson
Danaher Corporation
Genomic Health, Inc.
PacBio
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Indication
1.2.2. Technology
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Indication outlook
2.2.2. Technology outlook
2.2.3. Regional outlook
2.3. Competitive Insights
CHAPTER 3. PREDICTIVE BIOMARKERS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Predictive Biomarkers Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
CHAPTER 4. PREDICTIVE BIOMARKERS MARKET: INDICATION ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Predictive Biomarkers Market: Indication Movement Analysis
4.3. Predictive Biomarkers Market Size & Trend Analysis, by indication, 2018 to 2030 (USD Million)
4.4. Predictive Biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Cancer
4.5.1. Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Cardiovascular Diseases
4.6.1. Cardiovascular Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Neurological Diseases
4.7.1. Neurological Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Immunological Diseases
4.8.1. Immunological Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Others
4.9.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. PREDICTIVE BIOMARKERS MARKET: TECHNOLOGY ESTIMATES & TREND ANALYSIS
5.1. Technology Market Share, 2024 & 2030
5.2. Segment Dashboard
5.3. Global Predictive Biomarkers Market by Technology Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Diagnostics
5.5.1. Diagnostics Market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Drug Discovery & Development
5.6.1. Drug Discovery & Development Market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Personalized Medicine
5.7.1. Personalized Medicine Market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Disease Risk Assessment
5.8.1. Disease Risk Assessment Market estimates and forecasts 2018 to 2030 (USD Million)
5.9. Others
5.9.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. PREDICTIVE BIOMARKERS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.5. North America
6.5.1. North America: SWOT Analysis
6.5.2. U.S.
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/Reimbursement
6.5.2.3. Competitive scenario
6.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. Canada
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/Reimbursement
6.5.3.3. Competitive scenario
6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.5.4. Mexico
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/Reimbursement
6.5.4.3. Competitive scenario
6.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Europe
6.6.1. Europe: SWOT Analysis
6.6.2. UK
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/Reimbursement
6.6.2.3. Competitive scenario
6.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.6.3. Germany
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework/Reimbursement
6.6.3.3. Competitive scenario
6.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.6.4. France
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework/Reimbursement
6.6.4.3. Competitive scenario
6.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.6.5. Italy
6.6.5.1. Key country dynamics
6.6.5.2. Regulatory framework/Reimbursement
6.6.5.3. Competitive scenario
6.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.6.6. Spain
6.6.6.1. Key country dynamics
6.6.6.2. Regulatory framework/Reimbursement
6.6.6.3. Competitive scenario
6.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.6.7. Norway
6.6.7.1. Key country dynamics
6.6.7.2. Regulatory framework/Reimbursement
6.6.7.3. Competitive scenario
6.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.6.8. Sweden
6.6.8.1. Key country dynamics
6.6.8.2. Regulatory framework/Reimbursement
6.6.8.3. Competitive scenario
6.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.6.9. Denmark
6.6.9.1. Key country dynamics
6.6.9.2. Regulatory framework/Reimbursement
6.6.9.3. Competitive scenario
6.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Asia Pacific
6.7.1. Asia Pacific: SWOT Analysis
6.7.2. Japan
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/Reimbursement
6.7.2.3. Competitive scenario
6.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. China
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/Reimbursement
6.7.3.3. Competitive scenario
6.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.7.4. India
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/Reimbursement
6.7.4.3. Competitive scenario
6.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.7.5. Australia
6.7.5.1. Key country dynamics
6.7.5.2. Regulatory framework/Reimbursement
6.7.5.3. Competitive scenario
6.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.7.6. South Korea
6.7.6.1. Key country dynamics
6.7.6.2. Regulatory framework/Reimbursement
6.7.6.3. Competitive scenario
6.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.7.7. Thailand
6.7.7.1. Key country dynamics
6.7.7.2. Regulatory framework/Reimbursement
6.7.7.3. Competitive scenario
6.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.8. Latin America
6.8.1. Latin America: SWOT Analysis
6.8.2. Brazil
6.8.2.1. Key country dynamics
6.8.2.2. Regulatory framework/Reimbursement
6.8.2.3. Competitive scenario
6.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.8.3. Argentina
6.8.3.1. Key country dynamics
6.8.3.2. Regulatory framework/Reimbursement
6.8.3.3. Competitive scenario
6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.9. MEA
6.9.1. MEA: SWOT Analysis
6.9.2. South Africa
6.9.2.1. Key country dynamics
6.9.2.2. Regulatory framework/Reimbursement
6.9.2.3. Competitive scenario
6.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.9.3. Saudi Arabia
6.9.3.1. Key country dynamics
6.9.3.2. Regulatory framework/Reimbursement
6.9.3.3. Competitive scenario
6.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.9.4. UAE
6.9.4.1. Key country dynamics
6.9.4.2. Regulatory framework/Reimbursement
6.9.4.3. Competitive scenario
6.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.9.5. Kuwait
6.9.5.1. Key country dynamics
6.9.5.2. Regulatory framework
6.9.5.3. Competitive scenario
6.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2024
7.3.4. Thermo Fisher Scientific Inc.
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Services benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Qiagen
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Services benchmarking
7.3.5.4. Strategic initiatives
7.3.6. F. Hoffmann-La Roche Ltd
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Services benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Bio-Rad Laboratories, Inc
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Services benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Agilent Technologies, Inc.
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Services benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Illumina Inc.
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Services benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Merck KGaA
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Services benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Bio-Techne
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Services benchmarking
7.3.11.4. Strategic initiatives
7.3.12. Siemens Healthineers AG
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Services benchmarking
7.3.12.4. Strategic initiatives
7.3.13. PerkinElmer
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Services benchmarking
7.3.13.4. Strategic initiatives
7.3.14. Myriad Genetics, Inc.
7.3.14.1. Company overview
7.3.14.2. Financial performance
7.3.14.3. Services benchmarking
7.3.14.4. Strategic initiatives
7.3.15. Becton Dickinson
7.3.15.1. Company overview
7.3.15.2. Financial performance
7.3.15.3. Services benchmarking
7.3.15.4. Strategic initiatives
7.3.16. Danaher Corporation
7.3.16.1. Company overview
7.3.16.2. Financial performance
7.3.16.3. Services benchmarking
7.3.16.4. Strategic initiatives
7.3.17. Genomic Health, Inc.
7.3.17.1. Company overview
7.3.17.2. Financial performance
7.3.17.3. Services benchmarking
7.3.17.4. Strategic initiatives
7.3.18. PacBio
7.3.18.1. Company overview
7.3.18.2. Financial performance
7.3.18.3. Services benchmarking
7.3.18.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Indication
1.2.2. Technology
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Indication outlook
2.2.2. Technology outlook
2.2.3. Regional outlook
2.3. Competitive Insights
CHAPTER 3. PREDICTIVE BIOMARKERS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Predictive Biomarkers Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
CHAPTER 4. PREDICTIVE BIOMARKERS MARKET: INDICATION ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Predictive Biomarkers Market: Indication Movement Analysis
4.3. Predictive Biomarkers Market Size & Trend Analysis, by indication, 2018 to 2030 (USD Million)
4.4. Predictive Biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Cancer
4.5.1. Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Cardiovascular Diseases
4.6.1. Cardiovascular Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Neurological Diseases
4.7.1. Neurological Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Immunological Diseases
4.8.1. Immunological Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Others
4.9.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. PREDICTIVE BIOMARKERS MARKET: TECHNOLOGY ESTIMATES & TREND ANALYSIS
5.1. Technology Market Share, 2024 & 2030
5.2. Segment Dashboard
5.3. Global Predictive Biomarkers Market by Technology Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Diagnostics
5.5.1. Diagnostics Market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Drug Discovery & Development
5.6.1. Drug Discovery & Development Market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Personalized Medicine
5.7.1. Personalized Medicine Market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Disease Risk Assessment
5.8.1. Disease Risk Assessment Market estimates and forecasts 2018 to 2030 (USD Million)
5.9. Others
5.9.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. PREDICTIVE BIOMARKERS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.5. North America
6.5.1. North America: SWOT Analysis
6.5.2. U.S.
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/Reimbursement
6.5.2.3. Competitive scenario
6.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. Canada
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/Reimbursement
6.5.3.3. Competitive scenario
6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.5.4. Mexico
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/Reimbursement
6.5.4.3. Competitive scenario
6.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Europe
6.6.1. Europe: SWOT Analysis
6.6.2. UK
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/Reimbursement
6.6.2.3. Competitive scenario
6.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.6.3. Germany
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework/Reimbursement
6.6.3.3. Competitive scenario
6.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.6.4. France
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework/Reimbursement
6.6.4.3. Competitive scenario
6.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.6.5. Italy
6.6.5.1. Key country dynamics
6.6.5.2. Regulatory framework/Reimbursement
6.6.5.3. Competitive scenario
6.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.6.6. Spain
6.6.6.1. Key country dynamics
6.6.6.2. Regulatory framework/Reimbursement
6.6.6.3. Competitive scenario
6.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.6.7. Norway
6.6.7.1. Key country dynamics
6.6.7.2. Regulatory framework/Reimbursement
6.6.7.3. Competitive scenario
6.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.6.8. Sweden
6.6.8.1. Key country dynamics
6.6.8.2. Regulatory framework/Reimbursement
6.6.8.3. Competitive scenario
6.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.6.9. Denmark
6.6.9.1. Key country dynamics
6.6.9.2. Regulatory framework/Reimbursement
6.6.9.3. Competitive scenario
6.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Asia Pacific
6.7.1. Asia Pacific: SWOT Analysis
6.7.2. Japan
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/Reimbursement
6.7.2.3. Competitive scenario
6.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. China
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/Reimbursement
6.7.3.3. Competitive scenario
6.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.7.4. India
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/Reimbursement
6.7.4.3. Competitive scenario
6.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.7.5. Australia
6.7.5.1. Key country dynamics
6.7.5.2. Regulatory framework/Reimbursement
6.7.5.3. Competitive scenario
6.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.7.6. South Korea
6.7.6.1. Key country dynamics
6.7.6.2. Regulatory framework/Reimbursement
6.7.6.3. Competitive scenario
6.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.7.7. Thailand
6.7.7.1. Key country dynamics
6.7.7.2. Regulatory framework/Reimbursement
6.7.7.3. Competitive scenario
6.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.8. Latin America
6.8.1. Latin America: SWOT Analysis
6.8.2. Brazil
6.8.2.1. Key country dynamics
6.8.2.2. Regulatory framework/Reimbursement
6.8.2.3. Competitive scenario
6.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.8.3. Argentina
6.8.3.1. Key country dynamics
6.8.3.2. Regulatory framework/Reimbursement
6.8.3.3. Competitive scenario
6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.9. MEA
6.9.1. MEA: SWOT Analysis
6.9.2. South Africa
6.9.2.1. Key country dynamics
6.9.2.2. Regulatory framework/Reimbursement
6.9.2.3. Competitive scenario
6.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.9.3. Saudi Arabia
6.9.3.1. Key country dynamics
6.9.3.2. Regulatory framework/Reimbursement
6.9.3.3. Competitive scenario
6.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.9.4. UAE
6.9.4.1. Key country dynamics
6.9.4.2. Regulatory framework/Reimbursement
6.9.4.3. Competitive scenario
6.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.9.5. Kuwait
6.9.5.1. Key country dynamics
6.9.5.2. Regulatory framework
6.9.5.3. Competitive scenario
6.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2024
7.3.4. Thermo Fisher Scientific Inc.
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Services benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Qiagen
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Services benchmarking
7.3.5.4. Strategic initiatives
7.3.6. F. Hoffmann-La Roche Ltd
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Services benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Bio-Rad Laboratories, Inc
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Services benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Agilent Technologies, Inc.
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Services benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Illumina Inc.
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Services benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Merck KGaA
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Services benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Bio-Techne
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Services benchmarking
7.3.11.4. Strategic initiatives
7.3.12. Siemens Healthineers AG
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Services benchmarking
7.3.12.4. Strategic initiatives
7.3.13. PerkinElmer
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Services benchmarking
7.3.13.4. Strategic initiatives
7.3.14. Myriad Genetics, Inc.
7.3.14.1. Company overview
7.3.14.2. Financial performance
7.3.14.3. Services benchmarking
7.3.14.4. Strategic initiatives
7.3.15. Becton Dickinson
7.3.15.1. Company overview
7.3.15.2. Financial performance
7.3.15.3. Services benchmarking
7.3.15.4. Strategic initiatives
7.3.16. Danaher Corporation
7.3.16.1. Company overview
7.3.16.2. Financial performance
7.3.16.3. Services benchmarking
7.3.16.4. Strategic initiatives
7.3.17. Genomic Health, Inc.
7.3.17.1. Company overview
7.3.17.2. Financial performance
7.3.17.3. Services benchmarking
7.3.17.4. Strategic initiatives
7.3.18. PacBio
7.3.18.1. Company overview
7.3.18.2. Financial performance
7.3.18.3. Services benchmarking
7.3.18.4. Strategic initiatives
LIST OF TABLES
Table 1 List of abbreviations
Table 2 North America Predictive biomarkers market, by region, 2018 - 2030 (USD Million)
Table 3 North America Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 4 North America Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 5 U.S Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 6 U.S Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 7 Canada Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 8 Canada Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 9 Mexico Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 10 Mexico Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 11 Europe Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 12 Europe Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 13 UK Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 14 UK Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 15 Germany Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 16 Germany Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 17 France Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 18 France Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 19 Italy Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 20 Italy Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 21 Spain Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 22 Spain Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 23 Denmark Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 24 Denmark Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 25 Sweden Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 26 Sweden Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 27 Norway Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 28 Norway Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 29 Asia Pacific Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 30 Asia Pacific Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 31 Japan Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 32 Japan Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 33 China Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 34 China Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 35 India Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 36 India Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 37 Australia Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 38 Australia Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 39 South Korea Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 40 South Korea Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 41 Thailand Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 42 Thailand Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 43 Latin America Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 44 Latin America Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 45 Brazil Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 46 Brazil Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 47 Argentina Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 48 Argentina Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 49 MEA Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 50 MEA Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 51 South Africa Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 52 South Africa Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 53 Saudi Arabia Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 54 Saudi Arabia Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 55 UAE Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 56 UAE Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 57 Kuwait Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 58 Kuwait Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 1 List of abbreviations
Table 2 North America Predictive biomarkers market, by region, 2018 - 2030 (USD Million)
Table 3 North America Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 4 North America Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 5 U.S Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 6 U.S Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 7 Canada Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 8 Canada Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 9 Mexico Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 10 Mexico Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 11 Europe Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 12 Europe Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 13 UK Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 14 UK Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 15 Germany Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 16 Germany Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 17 France Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 18 France Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 19 Italy Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 20 Italy Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 21 Spain Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 22 Spain Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 23 Denmark Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 24 Denmark Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 25 Sweden Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 26 Sweden Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 27 Norway Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 28 Norway Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 29 Asia Pacific Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 30 Asia Pacific Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 31 Japan Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 32 Japan Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 33 China Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 34 China Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 35 India Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 36 India Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 37 Australia Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 38 Australia Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 39 South Korea Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 40 South Korea Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 41 Thailand Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 42 Thailand Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 43 Latin America Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 44 Latin America Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 45 Brazil Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 46 Brazil Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 47 Argentina Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 48 Argentina Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 49 MEA Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 50 MEA Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 51 South Africa Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 52 South Africa Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 53 Saudi Arabia Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 54 Saudi Arabia Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 55 UAE Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 56 UAE Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
Table 57 Kuwait Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
Table 58 Kuwait Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Predictive biomarkers market: market outlook
Fig. 14 Predictive biomarkers competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 Predictive biomarkers market driver impact
Fig. 20 Predictive biomarkers market restraint impact
Fig. 21 Predictive biomarkers market strategic initiatives analysis
Fig. 22 Predictive biomarkers market: Indication movement analysis
Fig. 23 Predictive biomarkers market: Indication outlook and key takeaways
Fig. 24 Cancer market estimates and forecasts, 2018 - 2030
Fig. 25 Cardiovascular Diseases market estimates and forecasts,2018 - 2030
Fig. 26 Neurological Diseases market estimates and forecasts,2018 - 2030
Fig. 27 Immunological Diseases market estimates and forecasts,2018 - 2030
Fig. 28 Others market estimates and forecasts,2018 - 2030
Fig. 29 Predictive biomarkers market estimates and forecast, 2018 - 2030
Fig. 30 Predictive biomarkers Market: Technology movement analysis
Fig. 31 Predictive biomarkers market: Technology outlook and key takeaways
Fig. 32 Diagnostics market estimates and forecasts, 2018 - 2030
Fig. 33 Drug Discovery & Development market estimates and forecasts, 2018 - 2030
Fig. 34 Personalized Medicine market estimates and forecasts, 2018 - 2030
Fig. 35 Disease Risk Assessment market estimates and forecasts, 2018 - 2030
Fig. 36 Others market estimates and forecasts,2018 - 2030
Fig. 37 Global Predictive biomarkers market: Regional movement analysis
Fig. 38 Global Predictive biomarkers market: Regional outlook and key takeaways
Fig. 39 Global Predictive biomarkers market share and leading players
Fig. 40 North America market share and leading players
Fig. 41 Europe market share and leading players
Fig. 42 Asia Pacific market share and leading players
Fig. 43 Latin America market share and leading players
Fig. 44 Middle East & Africa market share and leading players
Fig. 45 North America, by country
Fig. 46 North America
Fig. 47 North America market estimates and forecasts, 2018 - 2030
Fig. 48 U.S.
Fig. 49 U.S. market estimates and forecasts, 2018 - 2030
Fig. 50 Canada
Fig. 51 Canada market estimates and forecasts, 2018 - 2030
Fig. 52 Mexico
Fig. 53 Mexico market estimates and forecasts, 2018 - 2030
Fig. 54 Europe
Fig. 55 Europe market estimates and forecasts, 2018 - 2030
Fig. 56 UK
Fig. 57 UK market estimates and forecasts, 2018 - 2030
Fig. 58 Germany
Fig. 59 Germany market estimates and forecasts, 2018 - 2030
Fig. 60 France
Fig. 61 France market estimates and forecasts, 2018 - 2030
Fig. 62 Italy
Fig. 63 Italy market estimates and forecasts, 2018 - 2030
Fig. 64 Spain
Fig. 65 Spain market estimates and forecasts, 2018 - 2030
Fig. 66 Denmark
Fig. 67 Denmark market estimates and forecasts, 2018 - 2030
Fig. 68 Sweden
Fig. 69 Sweden market estimates and forecasts, 2018 - 2030
Fig. 70 Norway
Fig. 71 Norway market estimates and forecasts, 2018 - 2030
Fig. 72 Asia Pacific
Fig. 73 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 74 China
Fig. 75 China market estimates and forecasts, 2018 - 2030
Fig. 76 Japan
Fig. 77 Japan market estimates and forecasts, 2018 - 2030
Fig. 78 India
Fig. 79 India market estimates and forecasts, 2018 - 2030
Fig. 80 Thailand
Fig. 81 Thailand market estimates and forecasts, 2018 - 2030
Fig. 82 South Korea
Fig. 83 South Korea market estimates and forecasts, 2018 - 2030
Fig. 84 Australia
Fig. 85 Australia market estimates and forecasts, 2018 - 2030
Fig. 86 Latin America
Fig. 87 Latin America market estimates and forecasts, 2018 - 2030
Fig. 88 Brazil
Fig. 89 Brazil market estimates and forecasts, 2018 - 2030
Fig. 90 Argentina
Fig. 91 Argentina market estimates and forecasts, 2018 - 2030
Fig. 92 Middle East and Africa
Fig. 93 Middle East and Africa market estimates and forecasts, 2018 - 2030
Fig. 94 South Africa
Fig. 95 South Africa market estimates and forecasts, 2018 - 2030
Fig. 96 Saudi Arabia
Fig. 97 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 98 UAE
Fig. 99 UAE market estimates and forecasts, 2018 - 2030
Fig. 100 Kuwait
Fig. 101 Kuwait market estimates and forecasts, 2018 - 2030
Fig. 102 Market share of key market players - Predictive biomarkers market
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Predictive biomarkers market: market outlook
Fig. 14 Predictive biomarkers competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 Predictive biomarkers market driver impact
Fig. 20 Predictive biomarkers market restraint impact
Fig. 21 Predictive biomarkers market strategic initiatives analysis
Fig. 22 Predictive biomarkers market: Indication movement analysis
Fig. 23 Predictive biomarkers market: Indication outlook and key takeaways
Fig. 24 Cancer market estimates and forecasts, 2018 - 2030
Fig. 25 Cardiovascular Diseases market estimates and forecasts,2018 - 2030
Fig. 26 Neurological Diseases market estimates and forecasts,2018 - 2030
Fig. 27 Immunological Diseases market estimates and forecasts,2018 - 2030
Fig. 28 Others market estimates and forecasts,2018 - 2030
Fig. 29 Predictive biomarkers market estimates and forecast, 2018 - 2030
Fig. 30 Predictive biomarkers Market: Technology movement analysis
Fig. 31 Predictive biomarkers market: Technology outlook and key takeaways
Fig. 32 Diagnostics market estimates and forecasts, 2018 - 2030
Fig. 33 Drug Discovery & Development market estimates and forecasts, 2018 - 2030
Fig. 34 Personalized Medicine market estimates and forecasts, 2018 - 2030
Fig. 35 Disease Risk Assessment market estimates and forecasts, 2018 - 2030
Fig. 36 Others market estimates and forecasts,2018 - 2030
Fig. 37 Global Predictive biomarkers market: Regional movement analysis
Fig. 38 Global Predictive biomarkers market: Regional outlook and key takeaways
Fig. 39 Global Predictive biomarkers market share and leading players
Fig. 40 North America market share and leading players
Fig. 41 Europe market share and leading players
Fig. 42 Asia Pacific market share and leading players
Fig. 43 Latin America market share and leading players
Fig. 44 Middle East & Africa market share and leading players
Fig. 45 North America, by country
Fig. 46 North America
Fig. 47 North America market estimates and forecasts, 2018 - 2030
Fig. 48 U.S.
Fig. 49 U.S. market estimates and forecasts, 2018 - 2030
Fig. 50 Canada
Fig. 51 Canada market estimates and forecasts, 2018 - 2030
Fig. 52 Mexico
Fig. 53 Mexico market estimates and forecasts, 2018 - 2030
Fig. 54 Europe
Fig. 55 Europe market estimates and forecasts, 2018 - 2030
Fig. 56 UK
Fig. 57 UK market estimates and forecasts, 2018 - 2030
Fig. 58 Germany
Fig. 59 Germany market estimates and forecasts, 2018 - 2030
Fig. 60 France
Fig. 61 France market estimates and forecasts, 2018 - 2030
Fig. 62 Italy
Fig. 63 Italy market estimates and forecasts, 2018 - 2030
Fig. 64 Spain
Fig. 65 Spain market estimates and forecasts, 2018 - 2030
Fig. 66 Denmark
Fig. 67 Denmark market estimates and forecasts, 2018 - 2030
Fig. 68 Sweden
Fig. 69 Sweden market estimates and forecasts, 2018 - 2030
Fig. 70 Norway
Fig. 71 Norway market estimates and forecasts, 2018 - 2030
Fig. 72 Asia Pacific
Fig. 73 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 74 China
Fig. 75 China market estimates and forecasts, 2018 - 2030
Fig. 76 Japan
Fig. 77 Japan market estimates and forecasts, 2018 - 2030
Fig. 78 India
Fig. 79 India market estimates and forecasts, 2018 - 2030
Fig. 80 Thailand
Fig. 81 Thailand market estimates and forecasts, 2018 - 2030
Fig. 82 South Korea
Fig. 83 South Korea market estimates and forecasts, 2018 - 2030
Fig. 84 Australia
Fig. 85 Australia market estimates and forecasts, 2018 - 2030
Fig. 86 Latin America
Fig. 87 Latin America market estimates and forecasts, 2018 - 2030
Fig. 88 Brazil
Fig. 89 Brazil market estimates and forecasts, 2018 - 2030
Fig. 90 Argentina
Fig. 91 Argentina market estimates and forecasts, 2018 - 2030
Fig. 92 Middle East and Africa
Fig. 93 Middle East and Africa market estimates and forecasts, 2018 - 2030
Fig. 94 South Africa
Fig. 95 South Africa market estimates and forecasts, 2018 - 2030
Fig. 96 Saudi Arabia
Fig. 97 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 98 UAE
Fig. 99 UAE market estimates and forecasts, 2018 - 2030
Fig. 100 Kuwait
Fig. 101 Kuwait market estimates and forecasts, 2018 - 2030
Fig. 102 Market share of key market players - Predictive biomarkers market
